Cyclacel Pharmaceuticals
Manufacturing · Malaysia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10 Tower 11 Avenue 5 the Horizon L No 8,...Phone Number
+60 9085177330Website
www.cyclacel.comRevenue
<$5 MillionStock Symbol
CYCCIndustry
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.Explore more
Cyclacel Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Cyclacel Pharmaceuticals
Compare insights from companies similar to Cyclacel Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cyclacel Pharmaceuticals Tech Stack
A closer look at the technologies used by Cyclacel Pharmaceuticals
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cyclacel Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. Th... Read More
